Stereotaxis (NYSEAMERICAN:STXS) Stock Price Down 1.6% – Time to Sell?

Stereotaxis Inc. (NYSEAMERICAN:STXS)’s share price dropped 1.6% during mid-day trading on Wednesday . The stock traded as low as $2.47 and last traded at $2.49. Approximately 297,657 shares traded hands during trading, a decline of 45% from the average daily volume of 544,622 shares. The stock had previously closed at $2.53.

Analyst Ratings Changes

STXS has been the topic of several recent analyst reports. Roth Mkm restated a “buy” rating and issued a $4.00 target price on shares of Stereotaxis in a research note on Wednesday, November 12th. UBS Group set a $4.00 price target on shares of Stereotaxis in a report on Wednesday, November 5th. Citizens Jmp initiated coverage on shares of Stereotaxis in a research note on Tuesday, December 16th. They set a “market outperform” rating and a $4.00 price objective on the stock. Finally, Citigroup assumed coverage on shares of Stereotaxis in a research note on Tuesday, December 16th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $4.00.

Stereotaxis Stock Performance

The company’s 50-day moving average is $2.46 and its 200-day moving average is $2.64. The firm has a market cap of $232.37 million, a price-to-earnings ratio of -8.89 and a beta of 1.44.

Insider Activity

In related news, Director Paul J. Isaac purchased 20,000 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were acquired at an average cost of $2.24 per share, with a total value of $44,800.00. Following the completion of the purchase, the director directly owned 2,786,557 shares of the company’s stock, valued at $6,241,887.68. This trade represents a 0.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 17.77% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Prescott Group Capital Management L.L.C. boosted its position in Stereotaxis by 44.5% in the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 1,139,252 shares of the company’s stock valued at $2,415,000 after buying an additional 350,600 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Stereotaxis by 0.9% during the second quarter. Geode Capital Management LLC now owns 1,478,201 shares of the company’s stock valued at $3,135,000 after acquiring an additional 13,891 shares during the period. Warberg Asset Management LLC boosted its holdings in Stereotaxis by 260.1% in the second quarter. Warberg Asset Management LLC now owns 1,201,500 shares of the company’s stock valued at $2,547,000 after acquiring an additional 867,878 shares during the last quarter. Rhumbline Advisers increased its position in Stereotaxis by 223.7% in the second quarter. Rhumbline Advisers now owns 148,913 shares of the company’s stock worth $316,000 after purchasing an additional 102,916 shares during the period. Finally, Jane Street Group LLC bought a new stake in Stereotaxis during the 2nd quarter worth about $78,000. Institutional investors and hedge funds own 45.35% of the company’s stock.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.